NPI: 1265400501 · TALLAHASSEE, FL 32308 · End-Stage Renal Disease (ESRD) Treatment Clinic/Center · NPI assigned 03/11/2006
Authorized official WEY, SAMUEL controls 20+ related entities in our dataset. Read more
| Authorized Official | WEY, SAMUEL (VP, LICENSURE & CERTIFICATION) |
| NPI Enumeration Date | 03/11/2006 |
Other providers sharing the same authorized official: WEY, SAMUEL
| Provider | City | State | Total Paid |
|---|---|---|---|
| DVA HEALTHCARE RENAL CARE INC | NORTH HOLLYWOOD | CA | $16.47M |
| DVA HEALTHCARE RENAL CARE INC | DELANO | CA | $16.43M |
| DVA RENAL HEALTHCARE INC | LOS ANGELES | CA | $15.51M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $14.93M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $13.67M |
| DVA RENAL HEALTHCARE INC | OAKLAND | CA | $13.42M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $13.25M |
| DVA HEALTHCARE RENAL CARE INC | YUMA | AZ | $12.88M |
| DVA HEALTHCARE RENAL CARE INC | BAKERSFIELD | CA | $12.77M |
| DVA RENAL HEALTHCARE INC | FULLERTON | CA | $12.19M |
| DVA HEALTHCARE RENAL CARE INC | POMONA | CA | $11.96M |
| DVA RENAL HEALTHCARE INC | ANAHEIM | CA | $11.32M |
| DVA RENAL HEALTHCARE INC | ESCONDIDO | CA | $10.94M |
| DVA HEALTHCARE RENAL CARE INC | COSTA MESA | CA | $10.08M |
| DVA HEALTHCARE RENAL CARE INC | INGLEWOOD | CA | $9.46M |
| DVA RENAL HEALTHCARE INC | VISALIA | CA | $9.22M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $8.83M |
| DVA HEALTHCARE RENAL CARE INC | BAKERSFIELD | CA | $8.56M |
| DVA HEALTHCARE RENAL CARE INC | INGLEWOOD | CA | $7.78M |
| DVA RENAL HEALTHCARE INC | PALM SPRINGS | CA | $7.48M |
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 26,909 | $2.84M |
| 2019 | 23,151 | $2.33M |
| 2020 | 29,879 | $3.55M |
| 2021 | 20,789 | $1.19M |
| 2022 | 10,325 | $1.03M |
| 2023 | 7,220 | $453K |
| 2024 | 3,143 | $213K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 90999 | Unlisted dialysis procedure, inpatient or outpatient | 35,616 | 2,344 | $3.66M |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 37,109 | 1,594 | $2.91M |
| J1270 | Injection, doxercalciferol, 1 mcg | 23,363 | 1,389 | $2.06M |
| A4657 | Syringe, with or without needle, each | 5,460 | 1,704 | $1.00M |
| J1756 | Injection, iron sucrose, 1 mg | 6,485 | 1,309 | $552K |
| 83970 | 1,919 | 1,167 | $193K | |
| 82728 | 1,876 | 1,167 | $190K | |
| 83550 | 1,882 | 1,166 | $185K | |
| 83540 | 1,872 | 1,163 | $185K | |
| 85041 | 1,552 | 972 | $156K | |
| 85048 | 1,510 | 936 | $153K | |
| 85045 | 1,470 | 878 | $148K | |
| J0604 | Cinacalcet, oral, 1 mg, (for esrd on dialysis) | 382 | 62 | $104K |
| 82108 | 443 | 283 | $49K | |
| J0887 | Injection, epoetin beta, 1 microgram, (for esrd on dialysis) | 177 | 73 | $28K |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | 263 | 98 | $20K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 37 | 14 | $8K |